The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Orexigen Therapeutics Inc

Nasdaq: OREX(*D)
Last

(U.S.) $1.72

Today's change-0.06 -3.37%
Updated October 23 3:08 PM EDT. Delayed by at least 15 minutes.
 

Orexigen Therapeutics Inc

Nasdaq: OREX(*D)
Last

(U.S.) $1.72

Today's change-0.06 -3.37%
Updated October 23 3:08 PM EDT. Delayed by at least 15 minutes.

Orexigen Therapeutics Inc down (U.S.)$0.06

Orexigen Therapeutics Inc is sharply lower today, dropping (U.S.)$0.06 or 3.37% to (U.S.)$1.72. Shares have lost 6.01% over the last five days, but are unchanged over the last year to date. This security has underperformed the S&P 500 by 59.01% during the last year.

Key company metrics

  • Open(U.S.) $1.76
  • Previous close(U.S.) $1.78
  • High(U.S.) $1.77
  • Low(U.S.) $1.70
  • Bid / Ask(U.S.) $1.71 / (U.S.) $1.73
  • YTD % change-1.15%
  • Volume98,228
  • Average volume (10-day)620,075
  • Average volume (1-month)264,607
  • Average volume (3-month)132,187
  • 52-week range(U.S.) $1.65 to (U.S.) $5.70
  • Beta2.37
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$7.05
Updated October 23 3:08 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.05%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue2319147
Total other revenue--------
Total revenue2319147
Gross profit1713105
Total cost of revenue7642
Total operating expense656139-36
Selling / general / administrative48554235
Research & development8875
Depreciation / amortization2221
Interest expense (income), net operating--------
Unusual expense (income)1-11-161
Other operating expenses, total----0-80
Operating income-42-42-2543
Interest income (expense), net non-operating-1-1-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-31-69-2448
Income after tax-31-69-2548
Income tax, total----0--
Net income-31-69-2548
Total adjustments to net income--------
Net income before extra. items-31-69-2548
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-31-69-2548
Inc. avail. to common incl. extra. items-31-69-2548
Diluted net income-31-69-2548
Dilution adjustment--------
Diluted weighted average shares15151537
Diluted EPS excluding extraordinary itemsvalue per share-2.00-4.67-1.691.30
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-1.96-5.40-2.411.33